Wesana Health Holdings Inc.

Wesana Health Holdings Inc.

Wesana Health Holdings Inc. was originally formed as a life sciences company focused on developing psychedelic-assisted therapies for mental health conditions, including major depressive disorder and traumatic brain injury. The firm later pivoted its strategy away from direct drug development, citing challenges in the regulatory pathway for psychedelic compounds in the United States, and repositioned itself as a healthcare-focused investment and operating entity headquartered in Chicago. The firm's strategy centers on deploying capital across healthcare services, digital health platforms, and related therapeutic areas. While Wesana Health does not publicly disclose a specific AUM or deployment number, public filings and corporate communications indicate it has held equity positions in early-stage life sciences companies and has engaged in structured partnerships with clinical research organizations. The firm's geographic focus appears to be primarily North America. Wesana Health maintains a lean operational footprint, with its known operations concentrated in Chicago. The company has not disclosed team size, additional offices, or affiliated philanthropic vehicles. In 2023, the firm formally exited its lead drug development program, SPL-026, a pivotal operational event that signaled its broader strategic redirection away from psychedelic drug R&D and toward a more diversified healthcare asset management model. One structural differentiator of Wesana Health is its evolution from a clinical-stage biotech into a holding company with investment and operating capabilities — a less common trajectory than a pure asset manager or family office. The firm's governance and succession structure remain opaque, as it does not name a CEO or managing principal publicly in current materials.